See more : Johnson Electric Holdings Limited (JELCF) Income Statement Analysis – Financial Results
Complete financial analysis of Addex Therapeutics Ltd (ADXN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Addex Therapeutics Ltd, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Doseology Sciences Inc. (MOOD.CN) Income Statement Analysis – Financial Results
- Middle East Healthcare Company (4009.SR) Income Statement Analysis – Financial Results
- Banco Espírito Santo, S.A. (BKESF) Income Statement Analysis – Financial Results
- SHIFT UP (462870.KS) Income Statement Analysis – Financial Results
- RXR Acquisition Corp. (RXRAU) Income Statement Analysis – Financial Results
Addex Therapeutics Ltd (ADXN)
About Addex Therapeutics Ltd
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.61M | 1.42M | 2.92M | 3.61M | 2.76M | 6.04M | 499.89K | 17.33K | 40.30K | 85.40K | 91.76K | 121.09K | 2.82M | 1.98M | 4.09M | 26.81M | 486.93K | 4.74M |
| Cost of Revenue | 6.94M | 14.62M | 12.82M | 10.37M | 230.10K | 144.17K | 29.76K | 17.33K | 40.30K | 85.40K | 91.76K | 1.27M | 27.99M | 31.16M | 0.00 | 0.00 | -156.03K | 0.00 |
| Gross Profit | -5.32M | -13.20M | -9.90M | -6.76M | 2.53M | 5.90M | 470.13K | 0.00 | 0.00 | 0.00 | 0.00 | -1.15M | -25.16M | -29.19M | 4.09M | 26.81M | 642.96K | 4.74M |
| Gross Profit Ratio | -329.99% | -928.06% | -339.55% | -187.12% | 91.67% | 97.61% | 94.05% | 0.00% | 0.00% | 0.00% | 0.00% | -948.14% | -891.19% | -1,477.75% | 100.00% | 100.00% | 132.04% | 100.00% |
| Research & Development | 2.75M | 14.67M | 12.84M | 10.37M | 12.45M | 2.37M | 841.31K | 819.33K | 761.22K | 258.06K | 2.22M | 4.76M | 4.76M | 31.16M | 39.96M | 44.19M | 12.21M | 9.77M |
| General & Administrative | 7.20M | 7.30M | 5.14M | 5.15M | 4.27M | 4.72M | 2.20M | 1.52M | 1.57M | 1.55M | 6.47M | 12.85M | 6.73M | 6.43M | 7.60M | 7.55M | 10.77M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.20M | 7.30M | 5.14M | 5.15M | 4.27M | 4.72M | 2.20M | 1.52M | 1.57M | 1.55M | 6.47M | 12.85M | 6.73M | 6.43M | 7.60M | 7.55M | 10.77M | 0.00 |
| Other Expenses | 1.94M | -22.52K | 444.00K | 336.68K | 648.17K | 382.99K | 197.67K | 799.70K | 311.82K | -9.44K | 5.77M | 9.40M | -919.55K | -2.02M | 0.00 | -67.33K | 25.90M | 15.98M |
| Operating Expenses | 11.89M | 21.94M | 18.42M | 15.86M | 17.37M | 7.47M | 3.24M | 3.14M | 2.64M | 1.80M | 14.46M | 27.01M | 5.81M | 35.57M | 47.56M | 51.68M | 38.11M | 25.76M |
| Cost & Expenses | 11.89M | 21.94M | 18.42M | 15.86M | 17.37M | 7.47M | 3.24M | 3.14M | 2.64M | 1.80M | 14.46M | 27.01M | 33.80M | 35.57M | 47.56M | 51.68M | 38.11M | 25.76M |
| Interest Income | 63.96K | 29.25K | 5.32K | 35.31K | 36.87K | 85.87K | 0.00 | 27.00 | 39.86K | 1.59K | 4.13K | 22.66K | 72.20K | 97.25K | 362.13K | 3.31M | 2.55M | 241.99K |
| Interest Expense | 21.61K | 48.90K | 63.01K | 69.50K | 128.52K | 220.17K | 45.35K | 6.92K | 152.21K | 0.00 | 0.00 | 0.00 | 239.37K | 144.81K | 0.00 | 501.88K | 8.54K | 30.45K |
| Depreciation & Amortization | 305.95K | 323.14K | 347.61K | 378.75K | 333.84K | 2.94K | 15.25K | 25.76K | 25.88K | 110.14K | 662.55K | 2.10M | 2.93M | 2.94M | 2.84M | 2.02M | 1.80M | 2.52M |
| EBITDA | -10.23M | -20.23M | -14.94M | -12.41M | -14.32M | -1.51M | -3.22M | -3.12M | -2.61M | -1.71M | -13.79M | -24.87M | -28.05M | -30.56M | -39.86M | -19.55M | -33.26M | -17.99M |
| EBITDA Ratio | -634.16% | -1,417.83% | -519.59% | -327.42% | -515.18% | -23.52% | -644.10% | -17,979.05% | -6,488.51% | -1,998.26% | -15,026.90% | -20,542.67% | -990.78% | -1,547.10% | 1,112.94% | -72.92% | -6,833.66% | -380.48% |
| Operating Income | -10.28M | -20.52M | -15.51M | -12.24M | -14.83M | -1.42M | -3.24M | -3.13M | -3.87M | -1.80M | -14.46M | -27.01M | -30.97M | -33.60M | -43.05M | -24.87M | -37.62M | -20.90M |
| Operating Income Ratio | -637.42% | -1,442.61% | -531.70% | -338.88% | -536.92% | -23.57% | -647.15% | -18,059.88% | -9,597.64% | -2,103.69% | -15,756.97% | -22,306.25% | -1,097.02% | -1,700.93% | -1,052.47% | -92.78% | -7,726.28% | -441.03% |
| Total Other Income/Expenses | -274.93K | -284.01K | 154.00K | -615.33K | -176.45K | -220.17K | -45.35K | -19.79K | -1.56M | 748.35K | -3.23K | -8.41K | -167.17K | -47.56K | 85.75M | 2.81M | 2.54M | 355.32K |
| Income Before Tax | -10.56M | -20.80M | -15.35M | -12.86M | -14.78M | -1.64M | -3.28M | -3.15M | -4.20M | -1.77M | -14.46M | -26.61M | -31.14M | -33.65M | 42.69M | -22.07M | -35.09M | -20.54M |
| Income Before Tax Ratio | -654.47% | -1,462.57% | -526.42% | -355.92% | -534.98% | -27.21% | -656.22% | -18,174.08% | -10,432.03% | -2,078.19% | -15,760.49% | -21,976.79% | -1,102.95% | -1,703.33% | 1,043.62% | -82.32% | -7,205.50% | -433.53% |
| Income Tax Expense | 0.00 | 123.91K | 116.38K | 207.76K | 429.01K | 1.00 | 0.00 | 6.92K | 152.21K | -21.68K | 3.23K | -398.93K | 72.20K | 97.25K | 171.13M | 3.31M | 2.54M | 346.91K |
| Net Income | -10.56M | -20.80M | -15.35M | -12.86M | -14.78M | -1.64M | -3.28M | -3.15M | -4.20M | -1.77M | -14.46M | -26.61M | -31.14M | -33.65M | -42.69M | -22.07M | -35.09M | -20.54M |
| Net Income Ratio | -654.47% | -1,462.57% | -526.42% | -355.92% | -534.98% | -27.21% | -656.22% | -18,174.08% | -10,432.03% | -2,078.19% | -15,760.49% | -21,976.79% | -1,102.95% | -1,703.33% | -1,043.62% | -82.32% | -7,205.50% | -433.53% |
| EPS | -0.14 | -0.46 | -0.45 | -0.48 | -0.56 | -0.07 | -0.25 | -0.28 | -0.39 | -0.18 | -1.60 | -3.36 | -25.14 | -34.12 | -44.67 | -23.08 | -41.96 | -43.11 |
| EPS Diluted | -0.14 | -0.46 | -0.45 | -0.48 | -0.56 | -0.07 | -0.25 | -0.28 | -0.39 | -0.18 | -1.60 | -3.36 | -25.14 | -34.12 | -44.67 | -23.08 | -41.96 | -43.11 |
| Weighted Avg Shares Out | 74.31M | 45.18M | 34.12M | 26.68M | 26.43M | 23.29M | 12.94M | 11.41M | 10.85M | 9.98M | 9.07M | 7.91M | 1.24M | 986.06K | 955.78K | 956.03K | 836.15K | 476.53K |
| Weighted Avg Shares Out (Dil) | 74.31M | 45.18M | 34.12M | 26.68M | 26.43M | 23.29M | 12.94M | 11.41M | 10.85M | 9.98M | 9.07M | 7.91M | 1.24M | 986.06K | 955.78K | 956.03K | 836.15K | 476.53K |
Addex Therapeutics Ltd (ADXN) Q3 2024 Earnings Call Transcript
Addex Therapeutics Ltd (NASDAQ:ADXN ) Q3 2024 Earnings Conference Call November 22, 2024 10:00 AM ET Company Participants Tim Dyer - Co-Founder, Board Director and Chief Executive Officer Mikhail Kalinichev - Head, Translational Science Conference Call Participants Operator Good day,...
Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Indivior selected GABA B PAM drug candidate for development in substance use disorders (SUD) and starts IND enabling studies Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 22, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical...
Are Medical Stocks Lagging Addex Therapeutics (ADXN) This Year?
Here is how Addex Therapeutics Ltd. Sponsored ADR (ADXN) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024
Nine-month Results Remain On Track for Net Profit Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 11, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric...
What Makes Addex Therapeutics (ADXN) a New Buy Stock
Addex Therapeutics (ADXN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Addex Therapeutics Ltd (ADXN) Q2 2024 Earnings Call Transcript
Addex Therapeutics Ltd (NASDAQ:ADXN ) Q2 2024 Earnings Conference Call September 30, 2024 10:00 AM ET Company Participants Tim Dyer - Co-Founder, Board Director and Chief Executive Officer Misha Kalinichev - Head, Translational Science Conference Call Participants Raghuram Selvaraju -...
Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update
Launched Neurosterix with Perceptive Advisors to accelerate the development of M4PAM for schizophrenia Indivior selected GABA B PAM drug candidate for development in substance use disorders Addex selected independent GABAB PAM drug candidate for development in chronic cough Ad Hoc...
Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 19, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its...
Are Medical Stocks Lagging Addex Therapeutics (ADXN) This Year?
Here is how Addex Therapeutics Ltd. Sponsored ADR (ADXN) and Boston Scientific (BSX) have performed compared to their sector so far this year.
Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Geneva, Switzerland, September 4, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that CEO, Tim Dyer, will be attending the H.C. Wainwright...
Source: https://incomestatements.info
Category: Stock Reports